Everolimus Mitigates the Risk of Hepatocellular Carcinoma Recurrence after Liver Transplantation

Everolimus Mitigates the Risk of Hepatocellular Carcinoma Recurrence after Liver Transplantation

To obtain long-term data on the use of everolimus in patients who underwent liver transplantation for hepatocellular carcinoma, we conducted a retrospective, single-center analysis of adult recipients transplanted between 2013 and 2021. Patients on everolimus-incorporating immunosuppression were mat...

Full description

Bibliographic Details
Main Authors:	Paolo De Simone, Arianna Precisi, Quirino Lai, Juri Ducci, Daniela Campani, Piero Marchetti, Stefano Gitto
Format:	Article
Language:	English
Published:	MDPI AG 2024-03-01
Series:	Cancers
Subjects:	liver transplantation immunosuppression everolimus hepatocellular carcinoma recurrence
Online Access:	https://www.mdpi.com/2072-6694/16/7/1243

Similar Items

Efficiency of late conversion from mycophenolate mofetil to everolimus in kidney graft recipients with posttransplant malignancy
by: I. G. Kim, et al.
Published: (2018-01-01)

Impact of everolimus on survival after liver transplantation for hepatocellular carcinoma
by: Incheon Kang, et al.
Published: (2021-10-01)

Analysis of early use of everolimus with low-dose calcineurin inhibitors in kidney transplant recipient
by: I. G. Kim, et al.
Published: (2019-10-01)

PHARMACOECONOMIC ANALYSIS OF EVEROLIMUS IMMUNOSUPRESSIVE THERAPY AFTER RENAL TRANSPLANTATION
by: M. V. Avxentyeva, et al.
Published: (2015-06-01)

A systematic review and meta-analysis comparing everolimus and calcineurin inhibitors (CNIs) to mycophenolate and CNIs in kidney transplant patients
by: Larraine Vergara-Rejante, et al.
Published: (2023-03-01)

Everolimus and Bevacizumab in the Management of Recurrent, Progressive Intracranial NF2 Mutated Meningioma
by: Vinay Mathew Thomas, et al.
Published: (2019-01-01)

The management of post-transplantation recurrence of hepatocellular carcinoma
by: Luckshi Rajendran, et al.
Published: (2022-01-01)

Everolimus tedavisine bağlı interstisyel pnömoni
by: Nilüfer Aykaç Kongar, et al.
Published: (2016-12-01)

Management of Hepatocellular Carcinoma Recurrence after Liver Transplantation
by: Filippo Pelizzaro, et al.
Published: (2021-09-01)

Aging with a Liver Graft: Analysis of Very Long-Term Survivors after Liver Transplantation
by: Paolo De Simone, et al.
Published: (2024-02-01)

Combination of everolimus and low-dose tacrolimus controls histological liver allograft injury as sufficiently as high-dose tacrolimus
by: Emily A. Bosselmann, et al.
Published: (2023-04-01)

Changes in glomerular filtration rate in liver recipients after reduced exposure to calcineurin inhibitors with concomitant everolimus administration within the first year after immunosuppression conversion
by: V. E. Syutkin, et al.
Published: (2022-01-01)

Cross-sectional analysis of immunosuppressive regimens focused on everolimus after liver transplantation in a Korean high-volume transplantation center
by: Sang-Hyun Kang, et al.
Published: (2019-12-01)

FIRST EXPERIENCE IN SYSTEMIC ADMINISTRATION OF EVEROLIMUS IN RENAL TRANSPLANTATION FROM EXPANDED CRITERIA DONORS IN RUSSIAN FEDERATION
by: I. V. Uliyankina, et al.
Published: (2017-01-01)

Pharmaceutical support in liver transplantation at a reference center in Rio Grande do Sul
by: Mariana de Andrade Pranke, et al.
Published: (2017-03-01)

Laryngeal transplant: The future?
by: Varun Jitendra Dave
Published: (2016-01-01)

Pantoprazole Does not Affect Serum Trough Levels of Tacrolimus and Everolimus in Liver Transplant Recipients
by: Sebastian C. B. Bremer, et al.
Published: (2018-11-01)

The Role of Everolimus in Renal Cell Carcinoma
by: Malek Meskawi, et al.
Published: (2015-12-01)

Stepwise Reduction of Mycophenolate Mofetil with Conversion to Everolimus for the Treatment of Active BKV in Kidney Transplant Recipients: A Single-Center Experience in Vietnam
by: Truong Quy Kien, et al.
Published: (2022-12-01)

Metformin and Everolimus: A Promising Combination for Neuroendocrine Tumors Treatment
by: Eleonora Vitali, et al.
Published: (2020-08-01)

Toxic effects of sirolimus and everolimus on the development and behavior of zebrafish embryos
by: Zixin Zhang, et al.
Published: (2023-10-01)

Asphericity of Somatostatin Receptor Expression in Neuroendocrine Tumors: An Innovative Predictor of Outcome in Everolimus Treatment?
by: Christoph Wetz, et al.
Published: (2020-09-01)

Clinical Outcomes of Everolimus Rechallenge in Patients with Pancreatic Neuroendocrine Neoplasms with No Other Treatment Options
by: Yusuke Kurita, et al.
Published: (2022-11-01)

Experience of use of everolimus and long-acting somatostatin analogues combination in highly differentiated (G1-G2) neuroendocrine tumors
by: A A Markovich, et al.
Published: (2015-09-01)

Pneumocystis jirovecii pneumonia following everolimus treatment of metastatic breast cancer
by: Kelvin Teck-Hong Kuik, et al.
Published: (2014-10-01)

Everolimus in combination with octreotide LAR in thymic atypical carcinoid
by: Tadashi Sakane, et al.
Published: (2023-05-01)

Everolimus as a single agent in refractory or relapsed Hodgkin's lymphoma: the Brazilian Named Patient Program Experience
by: Talita Máira Bueno da Silveira da Rocha, et al.

Pharmacoeconomic analysis of everolimus immunosuppressive therapy for <i>de novo</i> kidney transplant recipients in Russia
by: N. A. Avxentyev, et al.
Published: (2019-05-01)

Can hepatocellular carcinoma recurrence be prevented after liver transplantation?
by: Jong Man Kim
Published: (2021-10-01)

Everolimus induced pulmonary thromboembolism after kidney transplantation; a case report
by: Fereshteh Saddadi, et al.
Published: (2022-01-01)

Effect and Complications of Everolimus Use for Giant Cardiac Rhabdomyomas with Neonatal Tuberous Sclerosis
by: Yuka Shibata, et al.
Published: (2019-07-01)

Activation of mTOR Signaling Pathway in Hepatocellular Carcinoma
by: Gustavo Ferrín, et al.
Published: (2020-02-01)

Everolimus Treatment and Selective Artery Embolization Application in a Case of Tuberous Sclerosis-Related Bilateral Renal Angiomyolipoma
by: Ismail Emre Ergin, et al.
Published: (2023-05-01)

The Impact of Everolimus and Radiation Therapy on Pulmonary Fibrosis
by: Mehmet Fuat Eren, et al.
Published: (2020-07-01)

Use of Everolimus to treat cardiac rhabdomyomas and incessant arrhythmias in a newborn: Benefits and complications
by: Eyal Sagiv, et al.
Published: (2022-01-01)

Oncological Impact of M-Tor Inhibitor Immunosuppressive Therapy after Liver Transplantation for Hepatocellular Carcinoma: Review of the Literature
by: Giuseppe Tarantino, et al.
Published: (2016-10-01)

Successful maternal and fetal outcomes in a kidney transplant patient under everolimus throughout pregnancy complicated by pyelonephritis and preeclampsia
by: Amina Ousti, MD, et al.
Published: (2022-11-01)

Everolimus Nanoformulation in Biological Nanoparticles Increases Drug Responsiveness in Resistant and Low-Responsive Breast Cancer Cell Lines
by: Arianna Bonizzi, et al.
Published: (2019-08-01)

Interactions between antifungals and everolimus against Cryptococcus neoformans
by: Pin Liang, et al.
Published: (2023-03-01)

EVEROLIMUS FOR KAPOSI'S SARCOMA TREATMENT AFTER KIDNEY TRANSPLANTATION
by: I. V. Alexandrov, et al.
Published: (2015-05-01)